Table 1.
Patient ID | Therapeutic Program | Age (Years) | BMI (kg/m2) | FIGO Stage | BRCA Gene Status | Nr. Cycles | PCI | CA125 at Diagnosis (U/mL) | Residual Disease (CC) | PFS (Months) | OS (Months) | Follow-Up State | Response to Platinum |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MiCrO 1 | neoadj | 51 | 20 | IV | WT | 15 | 16 | 1030 | CC-2 | 1 | 9 | DWD | PR |
MiCrO 2 | neoadj | 68 | 34 | IIIC | WT | 6 | 22 | 1800 | CC-0 | 10 | 21 | DWD | PR |
MiCrO 4 | neoadj | 71 | 25 | III | WT | 9 | 16 | 1256 | CC-0 | 24 | 39 | AWD | PS |
MiCrO 6 | neoadj | 71 | 21 | IIIC | WT | 10 | 20 | 1200 | CC-1 | 14 | 21 | DWD | PR |
MiCrO 8 | neoadj | 48 | 21 | III | BRCA1m | 6 | 18 | 999 | CC-0 | 15 | 16 | AWD | PS |
MiCrO 9 | neoadj | 58 | 24 | IV | WT | 8 | 25 | 1100 | CC-0 | 29 | 30 | NED | PS |
MiCrO 10 | neoadj | 56 | 20 | IIIC | WT | 9 | 27 | 2100 | CC-0 | 12 | 17 | DWD | PR |
MiCrO 16 | neoadj | 55 | 21 | III | BRCA2m | 6 | 25 | 1050 | CC-0 | 23 | 23 | AWD | PS |
MiCrO 23 | neoadj | 51 | 20 | IIIC | BRCA1m | 9 | 21 | 499 | CC-0 | 18 | 25 | AWD | PS |
MiCrO 24 | neoadj | 61 | 21 | III | WT | 13 | 24 | 499 | CC-0 | 13 | 13 | NED | PS |
MiCrO 25 | neoadj | 67 | 20 | IIIC | WT | 9 | 27 | 999 | CC-2 | 16 | 22 | AWD | PR |
MiCrO 28 | neoadj | 48 | 24 | IIIC | BRCA1m | 6 | 37 | 1030 | CC-0 | 12 | 12 | DWD | PR |
MiCrO 3 | adj | 69 | 23 | IIIC | WT | 6 | 18 | 1000 | CC-0 | 8 | 8 | NED | PS |
MiCrO 5 | adj | 61 | 23 | IIIC | WT | 6 | 17 | 750 | CC-1 | 14 | 21 | AWD | PS |
MiCrO 7 | adj | 57 | 21 | IV | WT | 6 | 29 | 1029 | CC-1 | 10 | 13 | DWD | PR |
MiCrO 11 | adj | 67 | 23 | IIIC | BRCA1m | 6 | 21 | 1340 | CC-0 | 11 | 18 | AWD | PR |
MiCrO 12 | adj | 43 | 22 | IIB | WT | 6 | 3 | 1000 | CC-0 | 13 | 13 | NED | PS |
MiCrO 13 | adj | 53 | 23 | IV | WT | 8 | 20 | 850 | CC-2 | 14 | 14 | AWD | PR |
MiCrO 17 | adj | 53 | 19 | IV | BRCA1m | 6 | 18 | 1000 | CC-0 | 17 | 18 | AWD | PS |
MiCrO 19 | adj | 57 | 20 | IC | BRCA1/2m | 6 | 0 | 679 | CC-0 | 15 | 15 | NED | PS |
MiCrO 22 | adj | 39 | 20 | IV | BRCA1m | 6 | 30 | 840 | CC-0 | 18 | 18 | AWD | PS |
MiCrO 31 | adj | 68 | 24 | IIIB | BRCA1m | 6 | 3 | 350 | CC-0 | 15 | 15 | AWD | PS |
MiCrO 33 | adj | 69 | 25 | IIIC | WT | 6 | 22 | 286 | CC-0 | 12 | 12 | NED | PS |
MiCrO 39 | adj | 54 | 32 | IIIC | WT | 6 | 11 | 453 | CC-0 | 10 | 10 | NED | PS |
Adj = adjuvant chemotherapy; AWD = alive with disease; BMI = body mass index; BRCAm = breast cancer gene mutation; CC = completeness cytoreduction; DWD = death with disease; FIGO = International Federation of Obstetrics and Gynecology; NED = no evidence of disease; Neoadj = neoadjuvant chemotherapy; OS = overall survival; PCI = peritoneal cancer index; PFS = progression-free survival; PR = platinum-resistant; PS = platinum-sensitive; WT = wild-type.